Codexis signs second agreement with Teva Pharmaceutical Industries

Codexis, Inc. today announced an expansion of its relationship and the signing of its second agreement this year with Teva Pharmaceutical Industries Ltd., the world's largest generic drug manufacturer. The new agreement covers three undisclosed pharmaceutical products. Codexis announced an earlier agreement with Teva on January 7.

Under the new agreement, Teva will use Codexis biocatalysis technology for key process steps in the manufacture of the covered generic products. Codexis develops proprietary custom biocatalysts which contribute to lower pharmaceutical process development and manufacturing costs. The company's technology is in use by leading drug companies worldwide. Financial terms were not disclosed.

"Expansion of our relationship with Teva from one to four products in under a year demonstrates the value of Codexis technology in today's competitive pharmaceuticals market," said Alan Shaw, Ph.D, Codexis President and Chief Executive Officer. "We are pleased to broaden our relationship with this major pharmaceuticals company."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers discover a new mechanism of resistance to KRAS inhibitors in pancreas cancer